Profiling of SDS-PAGE Based Differentially Expressed Proteins from Sera of Patients with Prostate Carcinoma

  • Roha Talat Center for Advanced Studies in Vaccinology and Biotechnology, University of Balochistan
  • Nargis Haider Kakar Department of Physiology, Bolan University of Medical and Health Sciences, Quetta, Pakistan.
  • Bushra Shaheen Department of Biochemistry, Independent Medical College, Faisalabad. Pakistan.
  • Shoaib Ahmad Malik Department of Biochemistry, Sargodha Medical College, University of Sargodha, Sargodha, Pakistan.
  • Muhammad Shahzad Farooq Department of Biochemistry, Faisalabad Medical University, Faisalabad, Pakistan.
  • Zunera Tanveer Department of Physiology, Bolan University of Medical and Health Sciences, Quetta, Pakistan.
  • Iqra Ayub Center for Advanced Studies in Vaccinology and Biotechnology, University of Balochistan
  • Asad ullah Center for Advanced Studies in Vaccinology and Biotechnology, University of Balochistan
  • Mohammad Zahid Mustafa Center for Advanced Studies in Vaccinology and Biotechnology, University of Balochistan
Keywords: Prostate cancer, SDS PAGE, Biomarkers

Abstract

Objective: This study “Profiling of SDS-PAGE based differentially expressed proteins from sera of patients with prostate carcinoma” provides an update on the novel candidate biomarkers in development, which have shown potential for improving the detection of clinically significant cases of this malignancy. Study Design: Cross sectional studies. Settings: Bolan Medical Complex and Civil Hospital Quetta Duration: From 08-01-2018 to 30-06-2018. Methodology: In this study, 50 serum samples were screened from prostate cancer patients and 10 from healthy donor sera using SDS PAGE in order to investigate the protein expressions in the form of bands. We compared these proteins with controls of healthy donors to find their upregulation Results: The results reveled the upregulation of proteins found in Prostate Cancer Patients as compare to healthy donors which were used as a control, which can further used as a biomarker for the diagnosis of early stage Prostate cancer. Conclusion: In the study we initially found 33 kDa, 34 kDa, 50 kDa, 75 kDa, and 100 kDa to be candidates for PCa progression biomarkers in Prostate cancer serum patients.

Published
2019-12-31